Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics Reports Second Quarter 2023 Financial Results
August 07, 2023 16:01 ET
|
Cara Therapeutics, Inc.
– 2Q23 total revenue of $6.9M including collaborative revenue of $5.4M from the Company’s share of profit of KORSUVA® (difelikefalin) injection – – Demand for KORSUVA injection accelerating with 46%...
Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors
August 03, 2023 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023
July 24, 2023 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., July 24, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2023 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
May 18, 2023 02:00 ET
|
Cara Therapeutics, Inc.
ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that...
Cara Therapeutics Reports First Quarter 2023 Financial Results
May 15, 2023 16:01 ET
|
Cara Therapeutics, Inc.
– 1Q23 total revenue of $6.2M including collaborative revenue of $2.8M from the Company’s share of profit of KORSUVA® (difelikefalin) injection – – Acceleration in demand for KORSUVA injection as...
Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023
May 01, 2023 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., May 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
April 10, 2023 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., April 10, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...